Charles River Laboratories International, Inc.
General ticker "CRL" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $8.1B (TTM average)
Charles River Laboratories International, Inc. follows the US Stock Market performance with the rate: 59.1%.
Estimated limits based on current volatility of 2.0%: low 160.57$, high 167.10$
Factors to consider:
- Earnings expected soon, date: 2026-05-06 bmo
- Company included in S&P500 list
- Total employees count: 20100 as of 2024
- US accounted for 55.3% of revenue in the fiscal year ended 2024-12-28
- Top business risk factors: Operational and conduct risks, Technology integration issues, Strategic risks and growth management, Realizing cost savings, Geopolitical risks
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-27 to 2027-12-27
- 2025-12-27 to 2026-12-27 estimated range: [172.31$, 253.09$]
- 2026-12-27 to 2027-12-27 estimated range: [174.20$, 256.89$]
Financial Metrics affecting the CRL estimates:
- Negative: with PPE of 19.3 at the end of fiscal year the price was high
- Positive: 7.68 < Operating profit margin, % of 12.65
- Positive: 6.68 < Operating cash flow per share per price, % of 7.49
- Negative: Inventory ratio change, % of 1.42 > 0.80
- Positive: -3.36 < Return on assets ratio (scaled to [-100,100]) of -1.95
- Positive: 42.60 < Shareholder equity ratio, % of 44.35 <= 64.25
- Positive: Industry inventory ratio change (median), % of 0.26 <= 0.31
- Positive: Interest expense per share per price, % of 1.09 <= 3.29
- Positive: -4.45 < Investing cash flow per share per price, % of -2.13
Short-term CRL quotes
Long-term CRL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-28 | 2025-12-27 |
|---|---|---|---|
| Operating Revenue | $4,129.41MM | $4,049.99MM | $4,015.38MM |
| Operating Expenses | $3,512.15MM | $3,822.64MM | $3,507.54MM |
| Operating Income | $617.26MM | $227.35MM | $507.84MM |
| Non-Operating Income | $-35.98MM | $-134.23MM | $-607.34MM |
| Interest Expense | $136.71MM | $126.29MM | $107.03MM |
| Income(Loss) | $581.28MM | $93.11MM | $-99.50MM |
| Taxes | $100.91MM | $67.82MM | $42.66MM |
| Profit(Loss)* | $474.62MM | $10.30MM | $-144.34MM |
| Stockholders Equity | $3,596.88MM | $3,461.50MM | $3,164.63MM |
| Inventory | $380.26MM | $278.54MM | $299.10MM |
| Assets | $8,195.00MM | $7,528.35MM | $7,135.42MM |
| Operating Cash Flow | $683.90MM | $734.58MM | $737.65MM |
| Capital expenditure | $318.53MM | $232.97MM | $219.15MM |
| Investing Cash Flow | $-563.15MM | $-245.09MM | $-209.32MM |
| Financing Cash Flow | $-85.52MM | $-550.93MM | $-536.73MM |
| Earnings Per Share** | $9.27 | $0.20 | $-2.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.